Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) – Analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research note issued to investors on Monday, June 9th. HC Wainwright analyst B. Folkes expects that the biotechnology company will earn $0.00 per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at $0.00 EPS, FY2026 earnings at $0.04 EPS, FY2027 earnings at $0.21 EPS, FY2028 earnings at $0.43 EPS and FY2029 earnings at $0.44 EPS.
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. The business had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million.
Read Our Latest Research Report on Heron Therapeutics
Heron Therapeutics Price Performance
Shares of HRTX opened at $2.01 on Wednesday. The stock has a market capitalization of $306.65 million, a price-to-earnings ratio of -11.17 and a beta of 1.16. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.75. The business’s 50 day simple moving average is $2.01 and its 200-day simple moving average is $1.89.
Institutional Trading of Heron Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Valeo Financial Advisors LLC raised its holdings in Heron Therapeutics by 34.1% during the 1st quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 4,619 shares during the period. Anfield Capital Management LLC raised its holdings in Heron Therapeutics by 5.6% during the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 6,264 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Heron Therapeutics by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 8,684 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Heron Therapeutics by 0.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after buying an additional 9,418 shares during the period. Finally, ProShare Advisors LLC raised its holdings in Heron Therapeutics by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 33,063 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 10,880 shares during the period. Hedge funds and other institutional investors own 80.01% of the company’s stock.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also
- Five stocks we like better than Heron Therapeutics
- Large Cap Stock Definition and How to Invest
- Ignore the Noise—Samsara Stock Is Still a Strong Buy
- Best Stocks Under $5.00
- 3 Stocks Set to Double—And There’s Still Time to Buy
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Analysts Can’t Get Enough of These Little-Known Biopharma Stocks
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.